Literature DB >> 2539998

Genetic profile of a nalidixic acid analog: a model for the mechanism of sister chromatid exchange induction.

H E Holden1, J F Barett, C M Huntington, P A Muehlbauer, M G Wahrenburg.   

Abstract

In recent years, evidence has accumulated that suggests that mammalian topoisomerase may play a role in the formation of spontaneous or chemically induced sister chromatid exchange (SCE). In microbial systems, nalidixic acid is known to disrupt the function of a topoisomerase-like enzyme, DNA gyrase. To explore the possible relationship to topoisomerase function and SCE formation in mammalian cells, an analog of nalidixic acid with potent topoisomerase II inhibitory activity was selected for examination in a variety of genetic toxicology assays. This analog, CP-67,015, proved to be a positive direct-acting mutagen in the L5178Y/TK+/-, CHO/HGPRT, and V79/HGPRT systems. However, no gene mutational activity was observed using the Ames test in direct plate, mouse and rat metabolic activation, and mouse urine tests. In vitro cytogenetic studies showed strong clastogenic activity in human lymphocytes and in CHO cells. Compound-induced chromosome damage was also observed in vivo in mouse bone marrow cells. Surprisingly, SCE studies in vitro in human lymphocytes or CHO cells showed only slight increases, even at levels producing severe chromosome breakage. Mouse bone marrow showed no significant elevation of SCE following parenteral treatment with CP-67,015. These results, taken together, demonstrate that CP-67,015 is a direct-acting mutagen in mammalian cells with both gene and chromosomal level effects. The relative ineffectiveness in producing SCEs suggests that CP-67,015 may interfere with a DNA replicative/repair process, perhaps by alteration of one or more DNA polymerase activities. This suggestion is based in part on the known effect of the analog nalidixic acid on DNA gyrase in microbial cells and on topoisomerase in mammalian cells. The profile of genetic activity of CP-67,015, coupled with its inhibitory effect on topoisomerase function, gives rise to a model for SCE formation that is based on anomalies of topoisomerase activity during DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539998     DOI: 10.1002/em.2850130308

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  11 in total

1.  Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Authors:  J F Barrett; T D Gootz; P R McGuirk; C A Farrell; S A Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

Authors:  K Hoshino; K Sato; K Akahane; A Yoshida; I Hayakawa; M Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 3.  Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.

Authors:  T D Gootz; J F Barrett; J A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 4.  In vitro assays used to measure the activity of topoisomerases.

Authors:  J F Barrett; J A Sutcliffe; T D Gootz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 5.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 6.  Quinolone mode of action--new aspects.

Authors:  D C Hooper
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  Mode of action of the new quinolones: new data.

Authors:  D C Hooper; J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

8.  Stimulation of genetic instability and associated large genomic rearrangements in Streptomyces ambofaciens by three fluoroquinolones.

Authors:  J N Volff; D Vandewiele; B Decaris
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Ofloxacin induces cytoplasmic respiration-deficient mutants in yeast Saccharomyces cerevisiae.

Authors:  M Obernauerová; J Subík; L Ebringer
Journal:  Curr Genet       Date:  1992-05       Impact factor: 3.886

Review 10.  Mutagenicity of quinolone antibacterials.

Authors:  F L Fort
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.